A Comparative Randomized Prospective Study to Evaluate Efficacy and Safety of Combination of Tamsulosin and Tadalafil vs. Tamsulosin or Tadalafil Alone in Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia

Journal of Sexual Medicine

Volumn 11, Issue 1, 2014, Pages 187-196

  Singh, Dig Vijay ^a   Mete, Uttam Kumar ^a   Mandal, Arup Kumar ^a   Singh, Shrawan Kumar ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Benign Prostatic Hyperplasia; Erectile Dysfunction; Lower Urinary Tract Symptoms; Medical Therapy; Tadalafil; Tamsulosin

Indexed keywords

TADALAFIL; TAMSULOSIN;

ADULT; ARTICLE; BACKACHE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; HEADACHE; HEARTBURN; HUMAN; HYPOTENSION; INTERNATIONAL INDEX OF ERECTILE FUNCTION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LABORATORY TEST; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYALGIA; OPEN STUDY; POSTVOID RESIDUAL URINE VOLUME; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESIDUAL URINE; RISK ASSESSMENT; TREATMENT OUTCOME; URINE FLOW RATE;

BENIGN PROSTATIC HYPERPLASIA; ERECTILE DYSFUNCTION; LOWER URINARY TRACT SYMPTOMS; MEDICAL THERAPY; TADALAFIL; TAMSULOSIN;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AGED; CARBOLINES; DRUG THERAPY, COMBINATION; ERECTILE DYSFUNCTION; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PENILE ERECTION; PHOSPHODIESTERASE 5 INHIBITORS; PROSPECTIVE STUDIES; PROSTATIC HYPERPLASIA; SULFONAMIDES; TREATMENT OUTCOME; URINARY RETENTION;

EID: 84892679432     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/jsm.12357     Document Type: Article

References (32)

1. Costabile RA, Steers WD. How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia? J Sex Med 2006;3:676-681.
2. Nicolosi A, Moreira ED Jr, Shirai M, Bin Mohd Tambi MI, Glasser DB. Epidemiology of erectile dysfunction in four countries: Cross-national study of the prevalence and correlates of erectile dysfunction. Urology 2003;61:201-206.
3. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: Results of the "Cologne Male Survey". Int J Impot Res 2000;12:305-311.
4. El-Sakka AI. Lower urinary tract symptoms in patients with erectile dysfunction: Analysis of risk factors. J Sex Med 2006;3:144-149.
5. Elliott SP, Gulati M, Pasta DJ, Spitalny GM, Kane CJ, Yee R, Lue TF. Obstructive lower urinary tract symptoms correlate with erectile dysfunction. Urology 2004;63:1148-1152.
6. McVary K. Lower urinary tract symptoms and sexual dysfunction: Epidemiology and pathophysiology. BJU Int 2006;97(suppl 2):23-28.
7. McVary K, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized, double-blind trial. J Urol 2007;177:1071-1077.
8. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Slides GD, Denes BS. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:1401-1407.
9. Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006;3:662-667.
10. Porst H, Roehrborn CG, Secrest RJ, Esler A, Viktrup L. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: Analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies. J Sex Med 2013;10:2044-2052.
11. Oger S, Behr-Roussel D, Gorny D, Charles Tremeaux J, Combes M, Alexandre L, Giuliano F. Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum. J Sex Med 2008;5:935-945.
12. Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007;51:1717-1723.
13. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TLJ, Roehrborn C. Efficacy and safety of long-term treatment with 5a-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46:488-495.
14. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
15. Ahmed I, El-Sakka AI. Lower urinary tract symptoms in patients with erectile dysfunction: Analysis of risk factors. J Sex Med 2006;3:144-149.
16. Chitale S, Collins R, Hull S, Smith E, Irving S. Is the current practice providing an integrated approach to the management of LUTS and ED in primary care? An audit and literature review. J Sex Med 2007;4:1713-1725.
17. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003;170:530-547.
18. Lue TF, Giuliano F, Montorsi F, Rosen RC, Andersson KE, Althof S, Christ G, Hatzichristou D, Hirsch M, Kimoto Y, Lewis R, McKenna K, MacMahon C, Morales A, Mulcahy J, Padma-Nathan H, Pryor J, de Tejada IS, Shabsigh R, Wagner G. Summary of the recommendations on sexual dysfunctions in men. J Sex Med 2004;1:6-23.
19. Porst H, Burnett A, Brock G, Ghanem H, Giuliano F, Glina S, Hellstorm W, Martin-Morales A, Salonia A, Sharlip I; ISSM Standards Committee for Sexual Medicine. SOP conservative (medical and mechanical) treatment of erectile dysfunction. J Sex Med 2013;10:130-171.
20. Kloner R, Jackson G, Emmick J, Mitchell M, Bedding A, Warner M, Pereira A. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004;172:1935-1940.
21. Kloner R. Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004;110:3149-3155.
22. Dunn ME, Althof SE, Perelman MA. Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction. Int J Impot Res 2007;19:119-123.
23. Porst H, McVary KT, Montorsi F, Sutherland P, Elion-Mboussa A, Wolka AM, Viktrup L. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009;56:727-735.
24. McMahon C. Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil. J Sex Med 2004;1:292-300.
25. Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses. J Urol 2002;168:1332-1336.
26. Bechara A, Romano S, Casabé A, Haime S, Dedola P, Hernandez C, Rey H. Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS/BPH. Pilot study. J Sex Med 2008;5:2170-2178.
27. Porst H, Rajfer J, Casabé A, Feldman R, Ralph D, Vieiralves LF, Esler A, Wolka AM, Klise SR. Long-term safety and efficacy of tadalafil 5mg dosed once daily in men with erectile dysfunction. J Sex Med 2008;5:2160-2169.
28. Liguori G, Trombetta C, De Giorgi G, Pomara G, Maio G, Vecchio D, Ocello G, Ollandini G, Bucci S, Belgrano E. Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: An integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. J Sex Med 2009;6:544-552.
29. De Rose AF, Giglio M, Traverso P, Lantieri P, Carmignani G. Combined oral therapy with sildenafil and doxazosin for the treatment of nonorganic erectile dysfunction refractory to sildenafil monotherapy. Int J Impot Res 2002;14:50-53.
30. Carson CC. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: Treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int 2006;97(2 suppl):39-43.
31. Giuliano F. Lower urinary tract symptoms and sexual dysfunction: A common approach. BJU Int 2008;101(3 suppl):22-26.
32. Angulo J, Cuevas P, Fernández A, La Fuente JM, Allona A, Moncada I, Saenz de Tejada I. Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck. J Sex Med 2012;9:2293-2306.